Literature DB >> 16907718

Azole antifungals as novel chemotherapeutic agents against murine tuberculosis.

Zahoor Ahmad1, Sadhna Sharma, G K Khuller.   

Abstract

The present study was designed to evaluate the in vivo antimycobacterial potential of econazole alone and in combination with antitubercular drugs against tuberculosis in mice. Econazole was found to reduce bacterial burden by 90% in the lungs and spleen of mice infected with 1 x 10(7) cells of Mycobacterium tuberculosis and was found to be equipotent to rifampicin. Further, our results indicate that econazole can replace rifampicin/isoniazid as well as both rifampicin and isoniazid in chemotherapy of murine tuberculosis. Econazole alone or in combination with antitubercular drugs did not produce any hepatotoxicity in normal or M. tuberculosis-infected mice.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16907718     DOI： 10.1111/j.1574-6968.2006.00350.x

Source DB:  PubMed          Journal:  FEMS Microbiol Lett        ISSN： 0378-1097            Impact factor:   2.742


  22 in total

1.  Targeting tuberculosis through a small focused library of 1,2,3-triazoles.

Authors:  Guillermo R Labadie; Agustina de la Iglesia; Héctor R Morbidoni
Journal:  Mol Divers       Date:  2011-06-02       Impact factor: 2.943

2.  In vitro activity of ACH-702, a new isothiazoloquinolone, against Nocardia brasiliensis compared with econazole and the carbapenems imipenem and meropenem alone or in combination with clavulanic acid.

Authors:  Lucio Vera-Cabrera; Mayra Paola Campos-Rivera; Wendy G Escalante-Fuentes; Michael J Pucci; Jorge Ocampo-Candiani; Oliverio Welsh
Journal:  Antimicrob Agents Chemother       Date:  2010-03-22       Impact factor: 5.191

Review 3.  The Mycobacterium tuberculosis cytochrome P450 system.

Authors:  Hugues Ouellet; Jonathan B Johnston; Paul R Ortiz de Montellano
Journal:  Arch Biochem Biophys       Date:  2009-07-25       Impact factor: 4.013

4.  The Structure of Mycobacterium tuberculosis CYP125: molecular basis for cholesterol binding in a P450 needed for host infection.

Authors:  Kirsty J McLean; Pierre Lafite; Colin Levy; Myles R Cheesman; Natalia Mast; Irina A Pikuleva; David Leys; Andrew W Munro
Journal:  J Biol Chem       Date:  2009-12-18       Impact factor: 5.157

5.  Advances in the treatment of pulmonary tuberculosis.

Authors:  Xia Zhang; Jing Guo
Journal:  J Thorac Dis       Date:  2012-12       Impact factor: 2.895

Review 6.  Microbial cytochromes P450: biodiversity and biotechnology. Where do cytochromes P450 come from, what do they do and what can they do for us?

Authors:  Steven L Kelly; Diane E Kelly
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2013-01-06       Impact factor: 6.237

7.  DevS, a heme-containing two-component oxygen sensor of Mycobacterium tuberculosis.

Authors:  Alexandra Ioanoviciu; Erik T Yukl; Pierre Moënne-Loccoz; Paul R Ortiz de Montellano
Journal:  Biochemistry       Date:  2007-03-20       Impact factor: 3.162

Review 8.  New drugs and regimens for treatment of TB.

Authors:  Eric Leibert; William N Rom
Journal:  Expert Rev Anti Infect Ther       Date:  2010-07       Impact factor: 5.091

9.  Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv.

Authors:  Kirsty J McLean; Paul Carroll; D Geraint Lewis; Adrian J Dunford; Harriet E Seward; Rajasekhar Neeli; Myles R Cheesman; Laurent Marsollier; Philip Douglas; W Ewen Smith; Ida Rosenkrands; Stewart T Cole; David Leys; Tanya Parish; Andrew W Munro
Journal:  J Biol Chem       Date:  2008-09-24       Impact factor: 5.157

10.  Interaction of Mycobacterium tuberculosis CYP130 with heterocyclic arylamines.

Authors:  Larissa M Podust; Hugues Ouellet; Jens P von Kries; Paul R Ortiz de Montellano
Journal:  J Biol Chem       Date:  2009-07-15       Impact factor: 5.157
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.